209 related articles for article (PubMed ID: 36980974)
1. Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells-A Preliminary Study.
Mizielska A; Dziechciowska I; Szczepański R; Cisek M; Dąbrowska M; Ślężak J; Kosmalska I; Rymarczyk M; Wilkowska K; Jacczak B; Totoń E; Lisiak N; Kopczyński P; Rubiś B
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980974
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
[TBL] [Abstract][Full Text] [Related]
3. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
4. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
[TBL] [Abstract][Full Text] [Related]
5. Dihydrotestosterone Induces Chemo-Resistance of Triple-Negative Breast MDA-MB-231 Cancer Cells Towards Doxorubicin Independent of ABCG2 and miR-328-3p.
Al-Momany B; Hammad H; Ahram M
Curr Mol Pharmacol; 2021; 14(5):860-870. PubMed ID: 34061013
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of oxidized low-density lipoprotein receptor 1 correlates with decreased miR-106b-5p, miR-93-5p, miR-3129-5p, miR-199b-3p, and miR-4465, higher recurrence rate, and poor prognosis in ovarian cancer.
Liu J; Zeng Y; Zheng L
Histol Histopathol; 2023 Apr; 38(4):475-485. PubMed ID: 36264049
[TBL] [Abstract][Full Text] [Related]
7. miR-101-3p and miR-199b-5p promote cell apoptosis in oral cancer by targeting BICC1.
Wang H; Guo Y; Mi N; Zhou L
Mol Cell Probes; 2020 Aug; 52():101567. PubMed ID: 32259627
[TBL] [Abstract][Full Text] [Related]
8. Differences of time-dependent microRNA expressions in breast cancer cells.
Bozkurt SB; Ozturk B; Kocak N; Unlu A
Noncoding RNA Res; 2021 Mar; 6(1):15-22. PubMed ID: 33385103
[TBL] [Abstract][Full Text] [Related]
9. Effect of Vinca Alkaloids on the Expression Levels of microRNAs Targeting Apoptosis-related Genes in Breast Cancer Cell Lines.
Mavrogiannis AV; Kokkinopoulou I; Kontos CK; Sideris DC
Curr Pharm Biotechnol; 2018; 19(13):1076-1086. PubMed ID: 30417784
[TBL] [Abstract][Full Text] [Related]
10. miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A.
Zhang Y; He Y; Lu LL; Zhou ZY; Wan NB; Li GP; He X; Deng HW
Kaohsiung J Med Sci; 2019 Jan; 35(1):17-23. PubMed ID: 30844143
[TBL] [Abstract][Full Text] [Related]
11. Alteration of miR-362-5p and miR-454-3p expression elicits diverse responses in breast cancer cell lines.
Aarthy R; Rao AKDM; Patel K; Sridevi V; Rajkumar T; Gowda H; Mani S
Mol Biol Rep; 2022 Jan; 49(1):821-826. PubMed ID: 34727290
[TBL] [Abstract][Full Text] [Related]
12. Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer.
Li M; Zhou Y; Xia T; Zhou X; Huang Z; Zhang H; Zhu W; Ding Q; Wang S
Breast Cancer Res Treat; 2018 Jul; 170(2):257-270. PubMed ID: 29557526
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines.
Uhr K; Prager-van der Smissen WJC; Heine AAJ; Ozturk B; van Jaarsveld MTM; Boersma AWM; Jager A; Wiemer EAC; Smid M; Foekens JA; Martens JWM
PLoS One; 2019; 14(5):e0216400. PubMed ID: 31063487
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-Induced Extracellular Vesicle miRNAs Promote Breast Cancer Stemness by Targeting
Shen M; Dong C; Ruan X; Yan W; Cao M; Pizzo D; Wu X; Yang L; Liu L; Ren X; Wang SE
Cancer Res; 2019 Jul; 79(14):3608-3621. PubMed ID: 31118200
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
Flores-Colón M; Rivera-Serrano M; Reyes-Burgos VG; Rolón JG; Pérez-Santiago J; Marcos-Martínez MJ; Valiyeva F; Vivas-Mejía PE
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612604
[TBL] [Abstract][Full Text] [Related]
16. Integrated Microarray-Based Data Analysis of miRNA Expression Profiles: Identification of Novel Biomarkers of Cisplatin-Resistance in Testicular Germ Cell Tumours.
Roška J; Lobo J; Ivovič D; Wachsmannová L; Mueller T; Henrique R; Jerónimo C; Chovanec M; Jurkovičová D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768818
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
[TBL] [Abstract][Full Text] [Related]
18. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
[TBL] [Abstract][Full Text] [Related]
19. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
Wang B; Li J; Sun M; Sun L; Zhang X
IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA profiling in serum: Potential signatures for breast cancer diagnosis.
Zou X; Xia T; Li M; Wang T; Liu P; Zhou X; Huang Z; Zhu W
Cancer Biomark; 2021; 30(1):41-53. PubMed ID: 32894240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
